FDA Approves New Indication for Promacta (eltrombopag)
LONDON, Nov. 19, 2012 -- GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.
There are limitations to the use of Promacta in patients suffering from chronic hepatitis C-associated thrombocytopenia. These include:
- Promacta should not be used in an attempt to normalize platelet counts;
- Promacta should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon therapy or limits the ability to maintain optimal interferon-based therapy; and
- Safety and efficacy have not been established in combination with direct-acting antiviral agents approved for treatment of chronic hepatitis C genotype 1 infection.
"Chronic hepatitis C is a significant public health issue," said Paolo Paoletti, M.D., President, GlaxoSmithKline Oncology. "Some chronic hepatitis C patients suffer from low blood platelet counts. Commonly prescribed interferon-based therapies can worsen the problem of low blood platelet counts. Today's FDA approval of Promacta gives doctors a tool to address the low platelet challenge. This means more chronic hepatitis C patients may be able to start and stay on interferon-based therapy. That gives these patients a better chance to achieve a viral cure."
The approval for Promacta is based on results from ENABLE 1 and 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE), two Phase III randomized, double-blind, placebo-controlled, multicenter studies, which collectively enrolled 1,521 patients with platelet counts <75,000/µL. ENABLE 1 utilized peginterferon alfa-2a (PEGASYS®) plus ribavirin for antiviral treatment and ENABLE 2 utilized peginterferon alfa-2b (PEGINTRON®) plus ribavirin.
Important Safety Information for Promacta
Promacta may cause hepatotoxicity. Promacta, in combination with interferon and ribavirin in patients with chronic hepatitis C, may increase the risk of hepatic decompensation. Patients receiving therapy with Promacta must have regular monitoring of serum liver tests (see Laboratory Monitoring). Discontinue Promacta if ALT levels increase to >/=3X upper limit of normal (ULN) in patients with normal liver function or >/= 3X baseline in patients with pre-treatment elevations in transaminases and are: progressive; or persistent for >/=4 weeks; or accompanied by increased direct bilirubin; or accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation. Reinitiating treatment with Promacta is not recommended and should be considered only with close medical supervision and under exceptional circumstances where the potential benefit outweighs the risk.
Additional Safety Information Regarding Risk of Hepatotoxicity:
Reinitiating treatment with Promacta is not recommended. If the potential benefit for reinitiating treatment with Promacta is considered to outweigh the risk for hepatotoxicity, then cautiously reintroduce Promacta and measure serum liver tests weekly during the dose adjustment phase. If liver test abnormalities persist, worsen or recur, then permanently discontinue Promacta.
Chronic hepatitis C patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alfa interferons. Monitor patients with low albumin levels or with MELD score ≥10 at baseline.
Thrombotic/thromboembolic complications may result from increases in platelet counts with Promacta. Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts. Consider the potential for an increased risk of thromboembolism when administering Promacta to patients with known risk factors for thromboembolism. To minimize the risk for thrombotic/thromboembolic complications, do not use Promacta in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain target platelet counts.
In 2 controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, 3% (31/955) treated with Promacta experienced a thrombotic event compared to 1% (5/484) on placebo. The majority of events were of the portal venous system (1% in patients treated with Promacta versus <1% for placebo).
In a controlled trial in non-ITP thrombocytopenic patients with chronic liver disease undergoing elective invasive procedures (N=292), seven thrombotic complications (six patients) were reported within the group that received Promacta and three thrombotic complications (two patients) within the placebo group. All of the thrombotic complications reported in the group that received Promacta were portal vein thrombosis, with thrombotic complications occurring in five of the six patients at a platelet count above 200 x 109/L. Promacta is not indicated for the treatment of thrombocytopenia in patients with CLD in preparation for invasive procedures.
Promacta must not be taken within 4 hours of any medications or products containing polyvalent cations such as antacids, dairy products, and mineral supplements.
The most common adverse reactions in 2 randomized placebo-controlled clinical trials in thrombocytopenic patients with chronic hepatitis C (>/=10% and greater than placebo) for Promacta versus placebo were: anemia (40% vs. 35%), pyrexia (30% vs. 24%), fatigue (28% vs. 23%), headache (21% vs. 20%), nausea (19% vs. 14%), diarrhea (19% vs. 11%), decreased appetite (18% vs. 14%), influenza?like illness (18% vs. 16%), asthenia (16% vs. 13%), insomnia (16 % vs. 15%), cough (15% vs. 12%), pruritus (15% vs. 13%), chills (14% vs. 9%), myalgia (12% vs. 10%), alopecia (10% vs. 6%), and peripheral edema (10% vs. 5%).
Promacta has both a BOXED WARNING and Medication Guide. Full Prescribing Information for physicians and Important Safety Information for consumers will be available soon at http://www.gsk.com/products/index.htm .
In the meantime, patients and physicians should visit the FDA Web site, www.fda.gov for important safety information.
About Chronic Hepatitis C Patients and ThrombocytopeniaApproximately 4.2 million people in the US have chronic hepatitis C, the most common blood-borne virus. It is estimated that up to 3.5% of these patients have platelet counts <75,000/µL, which could make them ineligible to start or maintain their interferon-based therapy.
About Promacta ® (eltrombopag)Eltrombopag, marketed under the brand names Promacta® in the U.S. and Revolade® in Europe and Rest-of-World, is a thrombopoietin receptor agonist approved in 90 countries around the world as a treatment for thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
In the United States, Promacta® is already indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2011.
Registered in England & Wales:
980 Great West Road
CONTACT: UK Media enquiries: London - David Mawdsley, +44 (0) 20 8047 5502, Sarah Spencer, +44 (0) 20 8047 5502, David Daley, +44 (0) 20 8047 5502, Catherine Hartley, +44 (0) 20 8047 5502, Alex Harrison, +44 (0) 20 8047 5502; US Media enquiries: Philadelphia - Anna Padula, +1-215-760-2928, Robert Perry, +1-407-492-4616; Analyst/Investor enquiries: Sally Ferguson, +44 (0) 20 8047 5543, (London), Lucy Budd, +44 (0) 20 8047 2248, (London), Tom Curry, +1-215-751-5419, (Philadelphia), Gary Davies, + 44 (0) 20 8047 5503, (London), James Dodwell, + 44 (0) 20 8047 2406, (London), Jeff McLaughlin, +1-215-751-7002, (Philadelphia), Ziba Shamsi, + 44 (0) 20 8047 3289, (London), all for GlaxoSmithKline
Web Site: http://www.gsk.com
Posted: November 2012
- FDA Approves New Indication for Promacta (eltrombopag) for Severe Aplastic Anemia - August 26, 2014
- FDA Approves Promacta (eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder - November 21, 2008
- Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for Promacta NDA - June 23, 2008
- Promacta (eltrombopag) Receives Unanimous Recommendation by FDA Advisory Panel - May 30, 2008
- FDA Grants Priority Review for Promacta (eltrombopag) - March 3, 2008
- Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for Promacta (eltrombopag) - December 21, 2007
- GlaxoSmithKline Files for FDA Approval of Promacta (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder - December 20, 2007